VIENNA – On track to file for regulatory approval later this year in both the U.S. and Europe, Intercept Pharmaceuticals Inc. solidified its position as a research leader in the nonalcoholic steatohepatitis (NASH) with liver fibrosis field, presenting a broader dataset of its phase III trial of obeticholic acid (OCA, Ocaliva).
VIENNA – Current FDA-approved options for patients infected with the hepatitis B virus (HBV) consist of immunomodulators, and nucleoside and nucleotide analogues, all of which target chronic disease and suppress virus replication, but do not cure HBV and leave no options for acute patients.
Less than a year after completing its $256 million IPO, South San Francisco-based Tricida Inc. presented robust phase III extension data for its chronic kidney disease (CKD) and metabolic acidosis candidate, TRC-101 (veverimer), paving the way for a new drug application filing through an accelerated pathway in the second half of this year.
Record-breaking financings in 2018 trickled down to almost every therapeutic area, showing in many cases double- and triple-digit percent increases of funds flowing into biopharma companies working on everything from cell and gene therapies to cancer immunotherapies and microbiome therapeutics.
Record-breaking financings in 2018 trickled down to almost every therapeutic area, showing in many cases double- and triple-digit percent increases of funds flowing into biopharma companies working on everything from cell and gene therapies to cancer immunotherapies and microbiome therapeutics.
Record-breaking financings in 2018 trickled down to almost every therapeutic area, showing in many cases double- and triple-digit percent increases of funds flowing into biopharma companies working on everything from cell and gene therapies to cancer immunotherapies and microbiome therapeutics.
With an agreement in hand to conduct research at the University of Pennsylvania's gene therapy center, as well as the expertise of scientist and company co-founder James Wilson, newly formed Passage Bio launched Thursday with a $115.5 million series A financing, money it will use toward rare monogenic central nervous system (CNS) diseases.
Biopharma companies lost significant stock market value in December and entered the New Year with a stranglehold on SEC filings due to the longest-ever government shutdown, so it is no wonder it took five weeks for the industry to complete its first IPO of 2019.
In every type of financing, from IPOs and follow-on public offerings to private placements and venture capital rounds, the med-tech industry produced more money and completed more financings in 2018 than the prior year, reflecting the same significant jump in activity seen with its biopharma counterpart.
In every type of financing, from IPOs and follow-on public offerings to private placements and venture capital rounds, the med-tech industry produced more money and completed more financings in 2018 than the prior year, reflecting the same significant jump in activity seen with its biopharma counterpart.
